Baidu
map

BMC Cancer:会阴部肿瘤切除术后,植入皮瓣的结局观察

2015-11-08 Seven L 译 MedSci原创

对会阴部癌症患者进行皮瓣重建,术后患者的结局和生活质量如何没有数据调查。研究者进行了一项研究评估晚期或复发性会阴部恶性肿瘤患者性行肌皮/皮肤皮瓣植入后的结局。该研究共纳入36名患者,其中 58.33 %的患者使用股前外侧皮瓣 (ALT),16.67 %的患者使用阴股沟皮瓣(PTF),11.11 %的患者使用腹壁下动脉穿支皮瓣 (DIEP),2.78 %的患者使用股薄肌肌皮瓣, 11.11 %的患者

对会阴部癌症患者进行皮瓣重建,术后患者的结局和生活质量如何没有数据调查。研究者进行了一项研究评估晚期或复发性会阴部恶性肿瘤患者性行肌皮/皮肤皮瓣植入后的结局。

该研究共纳入36名患者,其中 58.33 %的患者使用股前外侧皮瓣 (ALT),16.67 %的患者使用阴股沟皮瓣(PTF),11.11 %的患者使用腹壁下动脉穿支皮瓣 (DIEP),2.78 %的患者使用股薄肌肌皮瓣, 11.11 %的患者使用了2种皮瓣。

研究数据显示,11名(30.56%)患者出现了并发症,5名 (13.89 %)患者出现局部坏死,5名(13.89 %)患者出现了小的伤口裂开,1名(2.78 %)患者出现了皮瓣蜂窝织炎。局部坏死患者全部进行了再次手术。重建手术前后患者的平均口头评价得分分别为1.44和0.17(P < 0.0001)。平均性能状态手术前后分别为1.67和0.31,得到改善(P < 0.0001)。术后中位数随访时间9个月。重建术后21名(58.3 %)患者在间隔中位数5个月后出现了复发。中位数随访14个月后,41.7%的患者无疾病存活。纳入研究的36名患者的5年生存率为53.8%。

研究结果表明,对晚期/复发会阴部恶性肿瘤切除患者,进行软组织重建可降低术后并发症、减少疼痛、改善功能。尽管该人群的复发率依旧很高,不过重建对其仍有益。

原始出处:

Zhang W, Zeng A,et al.Outcome of vulvar reconstruction in patients with advanced and recurrent vulvar malignancies.BMC Cancer. 2015 Nov 5;15(1):851.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1974633, encodeId=93bb19e4633f5, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Oct 01 22:31:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876717, encodeId=571b18e671754, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sun Aug 07 10:31:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686938, encodeId=c20e1686938c4, content=<a href='/topic/show?id=468a82841d7' target=_blank style='color:#2F92EE;'>#肿瘤切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82841, encryptionId=468a82841d7, topicName=肿瘤切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c0b28305155, createdName=12498561m41(暂无昵称), createdTime=Tue Jul 26 02:31:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036265, encodeId=0ace203626527, content=<a href='/topic/show?id=366d25844f3' target=_blank style='color:#2F92EE;'>#会阴部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25844, encryptionId=366d25844f3, topicName=会阴部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Wed Mar 02 05:31:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425620, encodeId=6c4c1425620d7, content=<a href='/topic/show?id=e0cae1973bb' target=_blank style='color:#2F92EE;'>#皮瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71973, encryptionId=e0cae1973bb, topicName=皮瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9df03986056, createdName=sunylz, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513674, encodeId=1de215136e48e, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520282, encodeId=ada21520282c8, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1974633, encodeId=93bb19e4633f5, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Oct 01 22:31:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876717, encodeId=571b18e671754, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sun Aug 07 10:31:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686938, encodeId=c20e1686938c4, content=<a href='/topic/show?id=468a82841d7' target=_blank style='color:#2F92EE;'>#肿瘤切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82841, encryptionId=468a82841d7, topicName=肿瘤切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c0b28305155, createdName=12498561m41(暂无昵称), createdTime=Tue Jul 26 02:31:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036265, encodeId=0ace203626527, content=<a href='/topic/show?id=366d25844f3' target=_blank style='color:#2F92EE;'>#会阴部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25844, encryptionId=366d25844f3, topicName=会阴部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Wed Mar 02 05:31:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425620, encodeId=6c4c1425620d7, content=<a href='/topic/show?id=e0cae1973bb' target=_blank style='color:#2F92EE;'>#皮瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71973, encryptionId=e0cae1973bb, topicName=皮瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9df03986056, createdName=sunylz, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513674, encodeId=1de215136e48e, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520282, encodeId=ada21520282c8, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1974633, encodeId=93bb19e4633f5, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Oct 01 22:31:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876717, encodeId=571b18e671754, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sun Aug 07 10:31:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686938, encodeId=c20e1686938c4, content=<a href='/topic/show?id=468a82841d7' target=_blank style='color:#2F92EE;'>#肿瘤切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82841, encryptionId=468a82841d7, topicName=肿瘤切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c0b28305155, createdName=12498561m41(暂无昵称), createdTime=Tue Jul 26 02:31:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036265, encodeId=0ace203626527, content=<a href='/topic/show?id=366d25844f3' target=_blank style='color:#2F92EE;'>#会阴部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25844, encryptionId=366d25844f3, topicName=会阴部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Wed Mar 02 05:31:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425620, encodeId=6c4c1425620d7, content=<a href='/topic/show?id=e0cae1973bb' target=_blank style='color:#2F92EE;'>#皮瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71973, encryptionId=e0cae1973bb, topicName=皮瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9df03986056, createdName=sunylz, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513674, encodeId=1de215136e48e, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520282, encodeId=ada21520282c8, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1974633, encodeId=93bb19e4633f5, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Oct 01 22:31:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876717, encodeId=571b18e671754, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sun Aug 07 10:31:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686938, encodeId=c20e1686938c4, content=<a href='/topic/show?id=468a82841d7' target=_blank style='color:#2F92EE;'>#肿瘤切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82841, encryptionId=468a82841d7, topicName=肿瘤切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c0b28305155, createdName=12498561m41(暂无昵称), createdTime=Tue Jul 26 02:31:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036265, encodeId=0ace203626527, content=<a href='/topic/show?id=366d25844f3' target=_blank style='color:#2F92EE;'>#会阴部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25844, encryptionId=366d25844f3, topicName=会阴部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Wed Mar 02 05:31:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425620, encodeId=6c4c1425620d7, content=<a href='/topic/show?id=e0cae1973bb' target=_blank style='color:#2F92EE;'>#皮瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71973, encryptionId=e0cae1973bb, topicName=皮瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9df03986056, createdName=sunylz, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513674, encodeId=1de215136e48e, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520282, encodeId=ada21520282c8, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1974633, encodeId=93bb19e4633f5, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Oct 01 22:31:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876717, encodeId=571b18e671754, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sun Aug 07 10:31:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686938, encodeId=c20e1686938c4, content=<a href='/topic/show?id=468a82841d7' target=_blank style='color:#2F92EE;'>#肿瘤切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82841, encryptionId=468a82841d7, topicName=肿瘤切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c0b28305155, createdName=12498561m41(暂无昵称), createdTime=Tue Jul 26 02:31:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036265, encodeId=0ace203626527, content=<a href='/topic/show?id=366d25844f3' target=_blank style='color:#2F92EE;'>#会阴部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25844, encryptionId=366d25844f3, topicName=会阴部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Wed Mar 02 05:31:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425620, encodeId=6c4c1425620d7, content=<a href='/topic/show?id=e0cae1973bb' target=_blank style='color:#2F92EE;'>#皮瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71973, encryptionId=e0cae1973bb, topicName=皮瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9df03986056, createdName=sunylz, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513674, encodeId=1de215136e48e, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520282, encodeId=ada21520282c8, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=)]
    2015-11-10 sunylz
  6. [GetPortalCommentsPageByObjectIdResponse(id=1974633, encodeId=93bb19e4633f5, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Oct 01 22:31:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876717, encodeId=571b18e671754, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sun Aug 07 10:31:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686938, encodeId=c20e1686938c4, content=<a href='/topic/show?id=468a82841d7' target=_blank style='color:#2F92EE;'>#肿瘤切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82841, encryptionId=468a82841d7, topicName=肿瘤切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c0b28305155, createdName=12498561m41(暂无昵称), createdTime=Tue Jul 26 02:31:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036265, encodeId=0ace203626527, content=<a href='/topic/show?id=366d25844f3' target=_blank style='color:#2F92EE;'>#会阴部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25844, encryptionId=366d25844f3, topicName=会阴部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Wed Mar 02 05:31:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425620, encodeId=6c4c1425620d7, content=<a href='/topic/show?id=e0cae1973bb' target=_blank style='color:#2F92EE;'>#皮瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71973, encryptionId=e0cae1973bb, topicName=皮瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9df03986056, createdName=sunylz, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513674, encodeId=1de215136e48e, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520282, encodeId=ada21520282c8, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1974633, encodeId=93bb19e4633f5, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Oct 01 22:31:00 CST 2016, time=2016-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1876717, encodeId=571b18e671754, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sun Aug 07 10:31:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686938, encodeId=c20e1686938c4, content=<a href='/topic/show?id=468a82841d7' target=_blank style='color:#2F92EE;'>#肿瘤切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82841, encryptionId=468a82841d7, topicName=肿瘤切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c0b28305155, createdName=12498561m41(暂无昵称), createdTime=Tue Jul 26 02:31:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036265, encodeId=0ace203626527, content=<a href='/topic/show?id=366d25844f3' target=_blank style='color:#2F92EE;'>#会阴部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25844, encryptionId=366d25844f3, topicName=会阴部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Wed Mar 02 05:31:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425620, encodeId=6c4c1425620d7, content=<a href='/topic/show?id=e0cae1973bb' target=_blank style='color:#2F92EE;'>#皮瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71973, encryptionId=e0cae1973bb, topicName=皮瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9df03986056, createdName=sunylz, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513674, encodeId=1de215136e48e, content=<a href='/topic/show?id=1a4825835c5' target=_blank style='color:#2F92EE;'>#会阴#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25835, encryptionId=1a4825835c5, topicName=会阴)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=769010584396, createdName=ms5439512287675881, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520282, encodeId=ada21520282c8, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Nov 10 05:31:00 CST 2015, time=2015-11-10, status=1, ipAttribution=)]
    2015-11-10 jiyangfei

相关资讯

Cell Transplantation:干细胞移植可能对阿尔茨海默症有效

世界上患阿尔茨海默病(AD)的民众日益增加,痴呆患者的数量也在迅速增加,到2025年,患病人数可能有1亿人,但还没有有效的治疗方案。 佛罗里达州坦帕市的研究人员认为,干细胞移植治疗或许为治疗AD的可行方法。为此,他们着手探究这一方法,将人类脐血细胞(HUCBCs)注入AD小鼠体内,追踪这些细胞在大脑等组织的分布和留存,更好地探究人类脐带血细胞(HUCBCs)治疗AD这一方法的安全性和可行性。研究人

肿瘤液体活检技术:CTC和ctDNA孰优孰劣?

如果医生想深入了解肿瘤,他们的选择很有限。他们可以扫描相关区域、采集组织活检,或监控血液的标志物,如PSA或CA 125。不过,这些都不太理想:成像的分辨率不高,活检是侵入性的,而良好的标志物是少之又少。最理想的情况是,研究人员能通过简单的血液检测来实现组织活检的敏感性和特异性。如今,液体活检的出现,让这一切成为可能。液体活检据斯坦福大学医学院的助理教授Max Diehn介绍,就传统的癌症标志

Nature新研究找到增强癌症免疫治疗的新策略

                             (图片来自搜狐) 许多研究已经证明免疫疗法在对一些癌症病人的治疗过程中非常成功,但尽管有这些成功案例的存在,我们仍然注意到大部分病人并不会对这种治疗方法产生应答。  

我国五大恶性肿瘤筛查指南

癌症的早期筛查、诊断和治疗非常重要,有关专家指出,肺癌、胃癌、结直肠癌、肝癌、食管癌是我国发病率排名前五的恶性肿瘤,它们的共同特点是早期治疗效果好,较理想,到了中晚期转移复发概率高,因此抗癌的关键是早期筛查、诊断及治疗。  肺癌筛查方法:建议每年做一次低剂量CT筛查肺癌,如果CT发现肺部有阴影或小结,特别是磨玻璃样的阴影和小结,最好到正规大医院找有经验的医生看看,有必要的话可以做个病理活检。高危对

Nature:自噬能通过降解核纤层防止肿瘤的发生

Pennsylvania大学Perelman医学院的一项新研究,证实了自噬(Autophagy)也在细胞核中起作用,并且在这一情形下它发挥作用防止了癌症起病。 自噬与许多人类疾病密切相关。部分原因在于它对消化细胞中有可能导致问题的不利物质起作用。通过清除细胞中的这类“垃圾”,自噬充当了垃圾处理和回收系统帮助维持机体健康。 另一方面,功能失常的自噬与衰老及癌症、神经退行性疾病、肌肉疾病、糖尿病和

Cancer cell:基于肿瘤血小板的RNA测序精准诊断肿瘤新方法

近日,来自阿姆斯特丹自由大学的Myron G在《Cancer cell》发表的一篇文章提出,基于肿瘤血小板(Tumor-educated blood platelets,TEPs)的RNA测序可用于泛癌症分析、癌症类型的区分和肿瘤基因突变诊断。结果表明,血小板的RNA测序可以区分癌症患者与健康人,其准确率达到96%,也能区分六种原发肿瘤类型,其准确度达到71%,并能识别几种肿瘤中发现的基因改变。领

Baidu
map
Baidu
map
Baidu
map